Mineralys Therapeutics, Inc. (MLYS) has 11 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 3 sales totalling $2.9M. Most recent filing: Sept. 17, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 17, 2026 filed Sept. 15, 2026 | Karydas Daphne Director | $49,680 | 9,000 | 0% | Yes | |
|
|
||||||
| Aug. 25, 2026 filed Aug. 21, 2026 | Warren Eric Chief Commercial Officer | $94,723 | 22,311 | 0% | Yes | |
|
|
||||||
| Aug. 12, 2026 filed Aug. 10, 2026 | Ferguson James J. III Chief Medical Officer | $0 | 237,400 | +314% | No | |
|
|
||||||
| Aug. 12, 2026 filed Aug. 10, 2026 | Rodman David Malcom Chief Medical Officer | $24,065 | 6,510 | 0% | Yes | |
|
|
||||||
| July 23, 2026 filed July 21, 2026 | Warren Eric Chief Commercial Officer | $101,406 | 22,314 | 0% | Yes | |
|
|
||||||
Showing the 5 most recent of 11 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free